title: Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
abstract: We aimed to compare the cytogenetic and molecular analyses in the assessment of imatinib mesylate response in patients suffering the chronic phase of chronic myelocytic leukemia who were refractory to alpha-interferon treatment. A total of 117 patients in the chronic phase of chronic myelocytic leukemia were included. The patients were treated with 400 mg/day imatinib mesylate. Bone marrow samples were obtained for the cytogenetic and molecular analyses. Patients without the Ph chromosome were defined as complete cytogenetic responders. Partial cytogenetic response was determined when the Ph chromosome was detected in 1-35% of the cells. Molecular response was determined by quantitative real-time reverse transcriptase polymerase chain reaction (QR-PCR) and defined as no detection of BCR-ABL mRNA. The frequencies of complete and partial cytogenetic response were 29% (n = 34) and 15% (n = 18), respectively. No cytogenetic response was achieved in 56% (n = 65) of the patients. Molecular response was achieved in 62% (n = 21) and 33% (n = 6) of the complete and partial cytogenetic responders, respectively. All of the 65 patients with no cytogenetic response were also molecular nonresponders. We conclude that there is reasonable agreement between the cytogenetic and molecular analyses. Both methods are complementary in the assessment of response to therapy.
authors.affiliation: Division of Medical Genetics, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. spalanduz@istanbul.edu.tr
authors.forename: Sukru
authors.initials: S
authors.lastname: Palanduz
authors.forename: Aysegul
authors.initials: A
authors.lastname: Bayrak
authors.forename: Sema
authors.initials: S
authors.lastname: Sirma
authors.forename: Burcak
authors.initials: B
authors.lastname: Vural
authors.forename: Kivanc
authors.initials: K
authors.lastname: Cefle
authors.forename: Ali
authors.initials: A
authors.lastname: Ucur
authors.forename: Sukru
authors.initials: S
authors.lastname: Ozturk
authors.forename: Mustafa Nuri
authors.initials: MN
authors.lastname: Yenerel
authors.forename: Sevgi K
authors.initials: SK
authors.lastname: Besisik
authors.forename: Selim
authors.initials: S
authors.lastname: Yavuz
authors.forename: Reyhan
authors.initials: R
authors.lastname: Diz-Kucukkaya
authors.forename: Deniz
authors.initials: D
authors.lastname: Sargin
authors.forename: Meliha
authors.initials: M
authors.lastname: Nalcaci
authors.forename: Yuksel
authors.initials: Y
authors.lastname: Pekcelen
authors.forename: Ugur
authors.initials: U
authors.lastname: Ozbek
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D020732:Cytogenetic Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate